COMPOSITIONS AND METHODS FOR TREATMENT OF MUCOSAL INFECTIONS

Abstract: The present invention is concerned with novel compositions and vaccines useful for prophylactic and/or therapeutic treatment of mucosal infections, and in particular it is concerned with oral vaccines and with methods of enhancing mucosal resistance to infection or for treating established infections, of the respiratory tract.

Description: "Compositions and methods for treatment of mucosal infections" TECHNICAL FIELD The present invention is concerned with novel vaccine compositions that induce mucosal protection and in particular to oral vaccines and to methods of enhancing mucosal resistance to infection or for treating established infections. BACKGROUND ART Endobronchitis has been used as a model of mucosal immunology and more specifically to reflect a particular balance of the host-parasite relationship at the mucosal surface. The normally sterile bronchus mucosa becomes colonised by "avirulent" bacteria wliich do not generally invade. Most prominent is non-typable Haemophilus influenzae (NTHI). Acute episodes of infection in subjects with chronic lung disease are thus likely to be initiated by events which disturb a finely balanced relationship between colonising bacteria and the bronchus mucosa. The restraining host response involves Thl T cells (which produce γ interferon), which operate by recruiting and activating neutrophils within the bronchus mucosa. If excessive and/or inappropriate, this process leads to increase cough and purulent sputum, the hallmark of "acute bronchitis" in subjects with established chronic lung disease. The original oral vaccine used killed NTHI to activate the common mucosal system to enhance release of lymphocytes (then considered to be antibody producing B lymphocytes) from the Peyer's patches along the small intestine, which relocated within the bronchus mucosa, producing IgA antibody which would prevent descent of bacteria into the bronchi. This concept has been superseded. This vaccine requires that (i) a single bacterial content and (ii) no added adjuvant. The absence of adjuvant was thought necessary to avoid the then considered restrictions imposed by the highly downregulated mucosal environment, ie additions of adjuvant to a simple single bacterial vaccine would enhance mucosal downregulation, reduce vaccine effectiveness, and even promote or exacerbate infection. It is an object of the present invention to overcome or at least ameliorate one or more of the limitations of the prior art or to provide a useful alternative. SUMMARY OF THE INVENTION According to a first aspect there is provided a mucosally administrable composition comprising one or more antigens derived from at least one microorganism which is capable of causing infection at a mucosal surface and an adjuvant capable of inducing a Thl cellular immune response, wherein the adjuvant is not derived from a microorganism capable of causing infection at a mucosal surface. Preferably the antigen is derived from a bacterium, a fungus or a virus. Even more preferred is that the antigen is represented by the whole microorganism. As a further preference, when the antigen is a whole microorganism, it is a killed microorganism however it will be understood that live or live attenuated microorganisms may also be used effectively. It will also be understood however, that individual antigens or homogenates and sonicates of microorganisms can also be used with the expectation of achieving similar results. Particularly preferred are respiratory tract bacterial and fungal pathogens or those normally colonising the respiratory tract and having the potential to cause infection, for example NTE-I, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus albus, Staphylococcus aureus and the like, singularly or in combination. The compositions of the present invention are intended to be administered orally and thus may be combined with the known pharmaceutically acceptable, carriers, solvents and excipients. Preferably the adjuvant used in the compositions of the present invention is a microorganism or a part thereof which is not an organism that is capable of causing infection at a mucosal surface and wliich can induce a cellular immune response of the Thl type. Also preferred is that the adjuvant is a bacterium, for example one which can be selected from, but not limited to, lactic acid bacteria, Mycobacterium species or Bifidobacterium species. Even more preferred is the use of Lactobacillus acidophilus (L. acidophilus), Lactobacillus fermentum (L. fermentum) or Mycobacterium vaccae (M. vaccae), or parts thereof which are capable of inducing the Thl cellular response. Specially preferred is L. acidophilus. L. acidophilus, L. fermentum or M. vaccae may be used five or as an inactivated preparation, as long as they are capable of inducing the Thl response. For preference L. acidophilus and L. fermentum is used as a live preparation. It is considered that other bacteria would also be suitable as adjuvants (whether they have probiotic effect or not), for example the well known adjuvating bacteria such as for example L.casei, L. Plantarum, L. rhamnosus, Bifidobecterium breve and the like. The use of probiotic bacteria as adjuvants is preferred. Additional known conventional adjuvants may also be included. A range of suitable pharmaceutical adjuvants, excipients and carriers, and methods of preparing suitable formulations, would be well known to those skilled in the field of pharmaceutical formulation, and details of such adjuvants, excipients and carriers can be found in standard texts and manuals, such as for example "Remington: The Science and Practice of Pharmacy (Mack Publishing Co., 1995) which is incorporated in its entirety herein by reference. Further, the compositions of the present invention may be in the form of a food product or a food supplement, such as for example a dairy product or supplement. The methods of preparation of such products and supplements would also be clear to those skilled in the art, as they are well known procedures and processes, particularly those concerning the production of for example yoghurts and other milk products. According to a second aspect of the present invention there is provided a vaccine comprising the composition according to the first aspect. According to a third aspect there is provided a method of therapeutic or prophylactic treatment of a mucosal infection comprising the administration to a subject requiring such treatment a composition according to the first aspect or a vaccine according to the second aspect. It will be understood however that a subject requiring treatment, whether prophylactic or therapeutic, may be administered initially only a part of the composition, for example the adjuvant in the form of bacteria such as L. acidophilus and L. fermentum, followed thereafter by the administration of the antigen or antigens intended to ultimately provide specific immunity to the potential pathogen. The initial treatment with the adjuvant may take the form of a single bolus dose but may also, and for preference, be administered in repeated doses for a period of time before the antigen is administered. The administration of the adjuvant may also continue after cessation of antigen administration. As it is now clear that the mucosal immune system is common to all mucosal surfaces, the compositions and vaccines of the present invention can be applied to any potential mucosal pathogen and any mucosal surface, including but not limited to bucal cavity, the respiratory tract and the intestinal tract. Preferably the compositions or vaccines of the present invention are aclministered orally but application to any mucosal surface, for example the mucosa of the respiratory tract or mucosa of the intestinal tract, is contemplated. The compositions and vaccines of the present invention are advantageously used to induce mucosal protection against infection however they can also be used as prophylactics in the treatment of existing bacterial, fungal and/or viral mucosal infections. Further, the preferred use of the compositions and vaccines of the present invention is when the mucosal surfaces are already colonised by bacteria. Thus according to a fourth aspect there is provided a method of therapeutic or prophylactic treatment of a mucosal infection comprising the administration to a subject requiring such treatment the adjuvant part of a composition according to the first aspect, followed by the antigen part of a composition according to the first aspect. Preferably the treatment with the adjuvant part is by administration of a single bolus dose of adjuvant however treatment with the adjuvant part can also be by administration of repeated doses of adjuvant. More preferred however, is that the adjuvant and the antigen are co-administered. In a further embodiment of the invention, where the adjuvant is administered before or together with the antigen, the administration of the adjuvant may continue after the administration of the antigen part. The compositions and vaccines of the present invention may be administered to any mucosal surface and have the desired effect because of the common mucosal immune system. Preferred mucosal surfaces bucal cavity, the respiratory tract and the intestinal tract, however, as mentioned above, it will be understood by those skilled in this field that administration to any mucosal surface would be effective. Preferably the compositions or the vaccines are administered orally. Preferably, the vaccine is administered in two courses, followed by a booster course. The preferred dosage of the adjuvant, when the adjuvant is a whole live probiotic bacterium, is from about 1 x 10 8 to about 1 x 10 12 organisms. The preferred dosage of the antigen, when the antigen is represented by a whole killed microorganism, is from about 1 x 10 8 to about 1 x 10 12 organisms. More preferred is a dosage wherein the ratio of whole killed microorganisms (antigen) to probiotic bacteria (adjuvant) is about 5:1 or greater. Also preferred is the administration of the compositions or the vaccines, each year before outbreak of seasonal infections. BRIEF DESCRIPTION OF THE FIGURE Figure 1 : IL-4 and IFN-γ production following feeding with Lactobacillus acidophilus DESCRIPTION OF THE PREFERRED EMBODIMENTS It has been surprisingly found that by combining, for example, a specific antigen relevant to mucosal infection (eg whole bacteria such as Haemophilus influenzae) and non- specific bacteria, ie. those that are not normally associated with mucosal infection, protracted protection against mucosal infection can be achieved. Without wishing to be bound by any particular mechanism of action, the present invention is based on the notion that the non-specific bacteria used induce T cells to produce a particular cytokine response which amplifies the protection otherwise expected from administration of traditional vaccine preparations. More specifically, but again not wishing to be bound by any particular mechanism of action, it is thought that by the administration of non-specific bacteria the mucosal immune system is being biased towards the Thl (ie IFN-γ) end of the T cell response spectrum. It is considered that the Thl response best controls mucosal colonisation. The use of such organisms, and other adjuvants capable of stimulating a Thl response, determines a Thl response that is detectable and can have effects distant from the site of administration. It is demonstrated herein that a non-specific bacteria such as lactic acid bacteria, have the capacity to downregulate IL-4 and to enhance IFN-γ production in a highly "Th2- biased" murine model (see Example 1). It is also demonstrated herein that a non-specific bacterium such as lactobacillus provides additive protection in a rat model of non-typable Haemophilus influenzae (NTHI) clearance from the bronchus (shown to involve CD4 T cells, with no antibody) (see Example 2). The animal model used by way of example in the present studies is a model of colonisation, relevant to both therapy and prevention of infection. Colonisation is an essential determinant for infection and the model has been used in the context of other therapeutic and prophylactic vaccines to establish efficacy, dosage, dosage protocols and the like. In a particular embodiment of the present invention a therapeutic oral vaccine combines: 1) specific bacteria which are found within the respiratory tract, singly or in combination (for example, but not limited to, NTHI, S.pneumoniae, Ps.aeruginosa, S.albus, S.aureus), as killed or live bacteria, and 2) non-specific bacteria (also referred to herein as probiotic bacteria), which have the capacity to switch mucosal immunity in the direction of a Thl T cell response (may also be used killed or live), for example, but not limited to, Lactobacillus species (eg. L. acidophilus) and/ 'or Mycobacterium species, (eg M.vaccae). This type of oral vaccine operates best when the mucosal surface is already colonised (as these bacteria re-stimulate newly relocated cells within the mucosa) ie functions as a therapeutic vaccine. It can, however, function as a prophylactic vaccine. To avoid inactivation of bacteria by gastric acid, enteric coated capsules (or similar) may be used to release the bacterial contents along the small intestine. Another option is longer term use of the non-specific bacteria to create a more durable Thl mucosal environment, prior to the administration of the specific antigen(s) or bacteria intended to induce a specific immune response against the potential mucosal pathogen. The 'nonspecific' bacteria alone do not induce specific protection. The non-specific bacteria also enhance response to certain antigens given parenterally, particularly those influencing mucosal protection (by favouring a particular immune outcome). A combination of Gram+ve with Gram-ve bacteria as probiotic adjuvants has synergistic activity in this system and is also contemplated herein. Various respiratory mucosal surfaces can be protected as the mucosal immune system is common to all mucosal surfaces (eg bronchus, sinus, and middle ear among others). The invention will now be more particularly described with reference to specific, non-limiting, examples. Example 1: Effect of probiotic bacteria on Thl/Th2 cytokine response To determine whether probiotic bacteria down-regulate Th2 and up-regulate Thl cytokine response, C57/B16 mice were fed intragastrically using a feeding needle, various numbers of Lactobacillus acidophilus (obtained from University of New South Wales, School of Microbiology and Immunology Culture Collection, Sydney, Australia) on consecutive days for 2 weeks after which they were sensitised with 8 μg of ovalbumin (OVA) and aluminium hydroxide in 0.2 mL phosphate-buffered saline administered by peritoneal injection. The mice were further fed ten times with L. acidophilus every two days for two weeks before they were sacrificed. Lymphocytes were isolated by teasing spleens through a sieve, washed with PBS, and resuspended at 10 x 10 6 One mL aliquots of the cell suspension were dispensed into wells of a 24- well flat-bottomed microtitre plate and stimulated with OVA (5 μg/mL). After incubation for 4 days the supernatants were collected and assayed for IL-4 and LFN-γ production by standard ELISA techniques using IL-4 or IFN-γ monoclonal antibody pairs. Briefly, wells of a 24-well microtitre plate were coated with a capture anti-IL-4 antibody. After incubation at room temperature for 1 hr, the wells were washed and biotinylated anti-IL-4 antibody was added to each well. Following incubation for a further 1 hr, the wells were washed and strepavidin-peroxidase conjugate was added to each well. After incubation for 30 mins, the wells were washed and then TMB substrate was added. The colour development was read at 450/620 nm in an ELISA plate reader. The level of IL-4 in unknown samples was quantitated by intrapolation using a standard curve. A similar procedure was used for measurement of IFN-γ. The results shown in Fig. 1 A and B demonstrate that feeding L. acidophilus resulted in the suppression of IL-4 production in dose-dependent manner (Fig. 1A) whereas the production of IFN-γ was enhanced (Fig IB). Example 2: Enhanced clearance of NTHi from the respiratory tract induced by a single intra-lumenal dose of live L. acidophilus and killed NTHi The capacity of L. acidophilus to enhance clearance of non-typeable H influenzae (NTHI) from the respiratory tract was investigated in a rat model. DA rats (200-250 gm, 8-10 weeks old, Animal Resource Centre, Perth, WA ) were immunised by a single intra-lumenal (IL) injection (into the lumen of the small intestine) of 0.75 mL of PBS containing 5 x 10 9 killed NTHi alone or in combination with 2.5 x 10 10 L. acidophilus (as shown in Table 1). The IL dose was by direct injection into the intestinal lumen after exposing the duodenum by laparotomy. This is considered equivalent to an enteric-coated dose (as may be prepared for humans) being released into the gut lumen after oral ingestion. The rats were given an intra-tracheal (IT) boost with 50 μL of PBS alone (group A) or containing 5xl0 8 killed NTHI (groups B-D) on day 14. At day 21, the rats were infected intra-tracheally with 5 x 10 8 live NTHI in 50 μL of PBS. After 4 hrs, the rats were sacrificed and the total number of NTHI in bronchial lavage (BAL) and lung homogenate (LH) was determined by plating out serial 10-fold dilutions of the BAL or LH onto chocolate agar plates. After overnight incubation at 37°C the number of colonies were counted. The total number of bacteria in BAL and LH, expressed as colony forming units (CFU), as shown in Table 2. Table 1 : Rat groups: IL dose and IT boost a, p = 0.034 compared with group A b, p = 0.018 compared with group A c, p = 0.264 compared with group B d, p = 0.165 compared with group B p<0.05 is considered statistically significant This data shows that the combination of killed NTHi and live L. acidophilus is more efficacious than NTHi alone or L. acidophilus alone. Example 3 Enhanced clearance of NTHi from the lungs of immunised rats fed L acidophilus DA rats (200- 250 gm, 8-10 weeks old, Animal Resource Centre, Perth, WA) were fed by gavage with 5x10 10 L acidophilus in 1.0 mL PBS or PBS alone every 2 days for 7 days at which time the rats were immunised with formalin-killed NTHi (5 x 10 9 per rat) administered intralumenally (IL) in 0.5mL of PBS. Rats continued to be fed every 2 days for 2 weeks and were then boosted with 50 uL of PBS containing formalin killed NTHi (5 xlO 8 per rat) administered by the intratracheal (IT) route. After feeding with L. acidophilus for a further 7 days, the rats were infected IT with 50 uL of PBS containing 5 x 10 8 live NTHi. After 4 hrs, the levels of colonisation in the lung were determined in BAL and LH as described in Example 2. The immunization and feeding of the various groups is shown in Table 3. The bacterial recovery is shown in Table 4. Table 3: Rat groups: dosing regimens Table 4 Recover of live NTHi from the lun s a p = 0.011 compared with A g p = 0.235 compared with B b p = 0.018 compared with A hp statistically insignificant compared with B 0 p = 0.043 compared with A d p = 0.093 compared with A e p = 0.018 compared with A p = 0.033 compared with A Rats fed L acidophilus and immunised with killed NTHi were more resistant to infection by NTHi in the lungs than rats immunised with killed NTHi only or fed L. acidophilus only. Furthermore, rats fed by gavage with repeated doses of L acidophilus were more resistant to infection than rats given a single bolus of L. acidophilus (example 2). Not wishing to be bound by any particular mechanism of action, this data suggests that enhanced clearance may be due to increased colonisation in the gut with L. acidophilus following repeated feeding. Example 4: Intra-lumenal dosing with killed NTHi and live L. fermentum provides enhanced protection against a subsequent acute NTHi infection The capacity of L. fermentum to enhance clearance of NTHi, either alone or in combination with killed NTHi was evaluated in a rat model of acute NTHi respiratory infection. DA specific pathogen-free rats (177-200g) were obtained from the Central Animal house, University of Newcastle, Newcastle, NSW). Groups of 5 rats were given a single injection into the gut lumen of the small intestine of 0.75 mL of PBS only or PBS containing either 5xl0 9 killed NTHi only, 5xl0 9 killed NTHi plus 2.5xl0 10 L. fermentum, or 2.5xl0 10 L. fermentum only as shown in Table 5 below. On day 14, rats in group A were sham-boosted IT with 50 μL of PBS and rats in groups B-D were boosted with 50μL of PBS containing 5xl0 8 killed NTHi. On day 21 the rats were infected IT with 5x10 s live NTHi in 50μL of PBS. Four hours later rats were killed by an overdose of pentobarbitone administered intra-peritoneally. The lungs were lavaged with 10 mL of PBS to obtain broncho-alveolar lavage fluid (BAL). The lungs were then homogenised in 10 mL of PBS to obtain lung homogenate (LH). The number of bacteria in BAL and LH was determined by performing serial dilution of BAL and LH and plating known volumes on chocolate agar plates. After overnight incubation at 37°C the colonies were counted and the total number of colony-forming units (CFU) in BAL and LH determined. The number of bacteria in each rat group is shown in Table 6. Table 5: Rats (5 per group) were given a single intra-lumenal dose of various combinations of killed NTHi and live L. fermentum as follows: * compared to group A Also, for LH B>D (P = 0.041), and OD (P = 0.015). This data suggests that L. fermentum alone or with killed NTHi has greater efficacy as a prophylactic against subsequent acute respiratory infection than does killed NTHi alone. Thus, this lactobacillus strain is also effective against acute respiratory infection. Example 5: Dose-ranging study of X. acidophilus given with a fixed NTHi dose DA specific pathogen-free rats (197-230g) were obtained from the Central Animal house, University of Newcastle, Newcastle, NSW). Groups of 6 rats were given a single IL dose of PBS or a fixed dose of killed NTHi (5xl0 9 ) plus one of various doses of live L. acidophilus as shown in Table 7 below. On day 14, rats in group A were sham-boosted with 50 μL of PBS and rats in groups B-D were boosted with 50μL of PBS containing 5x10 s killed NTHi. Boosting was by intra-tracheal delivery. On day 21 the rats were infected by intra-tracheal instillation of 5xl0 8 live NTHi in 50μL of PBS. Four hours later rats were killed by an overdose of pentobarbitone administered intra-peritoneally. The lungs were lavaged with 10 mL of PBS to obtain broncho-alveolar lavage fluid (BAL). The lungs were then homogenised in 10 mL of PBS to obtain lung homogenate (LH). The number of bacteria in BAL and LH was detennined by performing serial dilution of BAL and LH and plating known volumes on chocolate agar plates. After overnight incubation at 37°C the colonies were counted and the total number of colony-forming units (CFU) in BAL and LH determined. The number of bacteria in each group is shown in Table 8. Table 7: Rat groups: IL dosing and IT boosting *compared to group A. The lower doses of lactobacillus are more effective than the higher doses. Again, without wishing to be bound by any particular mechanism of action, this dtata suggests that the 'adjuvant effect' may be operating differently from the lactobacillus- only effect. From the above data the equivalent dosage for humans is likely to be of the order of 1x10 s to lxlO 12 bacteria. Example 6: Evaluation of optimal dose-size/dose-regimen for NTHi immunization The optimal dose size and dosing regimen for killed NTHi immunization were determined. The different regimens evaluated are shown in Table 9. A single IL dose, a single IL dose followed by a gavage dose, and a single IL dose followed by two gavage doses were evaluated. Only one dose could be given IL as this involves surgery to expose the duodenum. Animal ethics considerations allow only one surgical intervention. Subsequent doses were therefore delivered by gavage. Table 9: Dosin re imens Results: (i Regimen 1 DA specific pathogen-free rats (187-213g) were obtained from the Central Animal house, University of Newcastle, Newcastle, NSW). Rats (6 per group) were given a single IL dose of killed NTHi as per regimen 1 in table 9, of various dose sizes as shown in Table 10. The killed NTHi was contained in 0.3 mL of PBS. The IT boost was with PBS (group A) or 2xl0 7 killed NTHI (groups B-D). Rats were infected intra-tracheally with 50uL of PBS containing 5x10 8 live NTHi. The bacteria recovered from BAL and LH is shown in Table 11. Table 10: Dose sizes tested in regimen 1 Table 11 : Recovery of live NTHi from the lung: Rat group BAL CFU (10 6 ) LH CFU qO 6 ) A (5) 1.12 ± 0.20 17.1 ± 1.9 B (6) 0.76± 0.14 P = 0.029 a 8.0 ± 1.5 P = 0.042* C __ 0.70 ± 0.20 P = 0.030 a 5.2 ± 1.4 P = 0.0006* D (6) 1.76 ± 0.37 16.1 ± 4.7 a compared to group D * compared to group A It is apparent that for a single immunizing IL-dose both the higher dose levels (3xl0 9 and 3x10 8 ) were equally effective in providing protective immunity. The lowest dose (3xl0 7 ) was ineffective. (ii) Regimen 2 DA specific pathogen-free rats (187-219g) were obtained from the Central Animal house, University of Newcastle, Newcastle, NSW). Rats (6 per group) were given a single IL dose of killed NTHi as per regimen 2 in table 9, of various dose sizes as shown in Table 12. The killed NTHi was contained in 0.3 mL of PBS. The IT boost was with PBS (group A) or 2xl0 7 killed NTHI (groups B-D) in 50 μL of PBS. Rats were infected intra- tracheally with 50μL of PBS containing 5xl0 8 live NTHi. The bacteria recovered from BAL and LH is shown in Table 13. Table 13: Recovery of live bacteria from the lung: * compared to group A. It is apparent that when two doses are given, all three dose sizes give the same degree of protection in LH. The level of protection is also comparable for the 3 doses in BAL but is only statistically significant for the highest dose in this experiment. (ii) Regimen 3 DA specific pathogen-free rats (176-213g) were obtained from the Central Animal house, University of Newcastle, Newcastle, NSW). Rats (6 per group) were given a single IL dose of killed NTHi as per regimen 3 in table 9, of various dose sizes as shown in Table 14. The killed NTHi was contained in 0.3 mL of PBS. The IT boost was with 50 μL of PBS (group A) or 2xl0 7 killed NTHI in 50 μL of PBS (groups B-D). Rats were infected intra-tracheally with 50uL of PBS containing 5xl0 8 live NTHi. The bacteria recovered from BAL and LH is shown in Table 15. Table 14: Dose sizes tested in re imen 3 Table 15: Recovery of live bacteria from the lung: *Compared to group A For 3 intestinal doses (one IL plus two by gavage) similar protection is provided by all three dose levels. There is no apparent advantage of three doses over two doses (regimen 2). From the above data the equivalent dosage for humans is likely to be of the order of lxlO 8 to lxlO 12 bacteria. Example 7: Long-term immunization with NTHi and L. acidophilus by a single IL dose. An experiment was performed to determine the duration of the enhanced protection provided by addition of L. acidophilus. DA specific pathogen-free rats (201- 293 g) were obtained from the Central Animal house, University of Newcastle, Newcastle, NSW). Groups of 6 rats were given an IL dose of 0.75 mL of PBS or PBS containing 5xl0 9 killed NTHI or a mixture of 5xl0 9 killed NTHi and 2.5 x 10 10 live L. acidophilus as shown in Table 16. Rats were IT boosted 14 days later with 50 μL of PBS or PBS containing 5x10 s killed NTHi as shown in Table 16. Three months after the IL dose rats were infected intra-tracheally (IT) with 5x10 s live NTHi in 50 μL of PBS. Four hours after infection rats were sacrificed and BAL and LH prepared for determination of total bacteria, measured as described in above examples and expressed as colony forming units (CFU). Table 16: Rat groups: IL dose and IT boost Table 17: Live bacteria recovered from the lung: Note: one rat in group D died during surgery to perform the IL dose. *compared to group A. Compared to group C. Over this 3 month experiment the immunization with NTHi alone was most effective. There is no apparent effect of additional L. acidophilus dosing over this time period. Although the present invention was described with reference to specific examples and preferred embodiments, it will be understood that variations in keeping with the broad concepts and the spirit of the invention herein described are also contemplated.

Claims: THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS :- 1. Mucosally administrable composition comprising one or more antigens derived from at least one microorganism which is capable of causing infection at a mucosal surface and an adjuvant capable of inducing a Thl cellular immune response, wherein the adjuvant is not derived from a microorganism capable of causing infection at a mucosal surface. 2. A composition according to claim 1, wherein the antigen is derived from a bacterium, a fungus or a virus. 3. A composition according to claim 1 or claim 2, wherein the antigen is represented by the whole microorganism. 4. A composition according to claim 3, wherein the whole microorganism is a killed microorganism 5. A composition according to claim 4, wherein the live microorganism is a live or a live attenuated microorganism. 6. A composition according to claim 1 or claim 2, wherein the antigen is represented by a homogenate or sonicate of one or more microorganisms. 7. A composition according to any one of claims 1 to 6, wherein the microorganism is a respiratory tract bacterial and/or fungal pathogen or a microorganism normally colonising the respiratory tract and having the potential to cause infection. 8. A composition according to claim 7, wherein the microorganism is selected from the group consisting of non-typable Heamophilus influenzae (NTHI), Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus albus, and Staphylococcus aureus, or any combination thereof. 9. A composition according to any one of claims 1 to 8, wherein the adjuvant is a microorganism or a part thereof, which is not an organism that is capable of causing infection at a mucosal surface and which can induce a cellular immune response of the Thl type. 10. A composition according to claim 9, wherein the adjuvant is a bacterium. 11. A composition according to claim 10, wherein the bacterium is selected from the group consisting of lactic acid bacteria, Mycobacterium species and Bifidobacteria, or a combination thereof. 12. A composition according to claim 11 , wherein the bacterium is selected from the group consisting Lactobacillus acidophilus, Lactobacillus fermentum and Mycobacterium vaccae , or parts thereof, which are capable of inducing the Thl cellular response. 13. A composition according to claim 12, wherein the bacterium is Lactobacillus acidophilus. 14. A composition according to any one of claims 9 to 13, wherein the bacterium is live. 15. A composition according to any one of claims 1 to 14, wherein the composition is an orally administrable composition. 16. A composition according to claim 15, further comprising one or more pharmaceutically acceptable carriers, adjuvants, solvents or excipients. 17. A composition according to any one of claims 1 to 15, which is a food or a food supplement. 18. A vaccine comprising a composition according to any one of claims 1 to 15. 19. Method of therapeutic or prophylactic treatment of a mucosal infection comprising the administration to a subject requiring such treatment a composition according to any one of claims 1 to 16, or of a vaccine according to claim 18. 20. Method of therapeutic or prophylactic treatment of a mucosal infection comprising the administration to a subject requiring such treatment the adjuvant part of a composition according to any one of claims 1 to 16, followed by the antigen part of a composition according to any one of claims 1 to 16. 21. Method according to claim 20, wherein the treatment with the adjuvant part is by administration of a single bolus dose of adjuvant 22. Method according to claim 20, wherein the treatment with the adjuvant part is by administration of repeated doses of adjuvant. 23. Method according to claim 20 or claim 22, wherein the administration of the adjuvant continues after the administration of the antigen part. 24. Method according to any one of claims 19 to 23, wherein the compound or the vaccine is administered to any mucosal surface. 25. Method according to claim 24, wherein the mucosal surface is selected from the group consisting of bucal cavity, the respiratory tract and the intestinal tract. 26. Method according to any one of claims 19 to 25, wherein the composition or the vaccine is administered orally. 27. Method according to any one of claims 19 to 26, wherein the vaccine is administered in two courses, followed by a booster course. 28. Method according to any one of claims 19 to 27, wherein the adjuvant is a bacterium and wherein the amount of bacteria administered is from about 1 x 10 s to about 1 x 10 12 organisms. 29. Method according to any one of claims 19 to 28, wherein the antigen is represented by a whole killed microorganism and wherein the amount of microorganisms is administered is from about 1 x 10 8 to about 1 x 10 12 organisms. 30. Method according to claim 28 or claim 29, wherein the ratio of whole killed microorganisms to adjuvant bacteria is about 5:1 or greater.

Inventors: CLANCY ROBERT LLEWELLYN, DUNKLEY MARGARET LORRAINE, PANG GERALD, CLANCY, ROBERT, LLEWELLYN, DUNKLEY, MARGARET, LORRAINE, PANG, GERALD
Applicants: CLANCY ROBERT LLEWELLYN, DUNKLEY MARGARET LORRAINE, PANG GERALD, PNEUMOBIOTICS PTY LTD, CLANCY, ROBERT, LLEWELLYN, DUNKLEY, MARGARET, LORRAINE, PANG, GERALD, PNEUMOBIOTICS, PTY, LTD
Application year: 2001
Main classification: A61K39
IPC codes: A61K39, A61P11, A61P31